Earnings Releases·Nov 5, 2026, 4:14 PM ET

Rezolute — First Quarter Fiscal 2027 Earnings Summary

Net loss widened to $18.5 million from $18.2 million year-over-year, with basic and diluted loss per share remaining flat at $0.18; total operating expenses decreased to $19.4 million from $19.8 million in the prior year period.
Cash and investments declined to $90.0 million as of September 30, 2026, from $107.8 million in June 2026, while accumulated deficit increased to $(499.9) million.
Management plans to submit a Biologics License Application (BLA) for ersodetug in 2027 for tumor HI and/or congenital HI, with Phase 3 upLIFT topline results expected by mid-December 2026.
Clinical updates indicate the Phase 3 upLIFT study met its primary endpoint in 7 of 8 participants, whereas the Phase 3 sunRIZE study missed its primary endpoint for congenital HI despite positive CGM-based trends.